Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Pancreatitis Risk with Linagliptin in Type 2 Diabetes

Clinical Considerations

  • The American Diabetes Association's 2025 Standards of Care lists pancreatitis as a potential safety concern for DPP-4 inhibitors, including linagliptin 1
  • The ADA guidelines specifically state: "Pancreatitis has been reported, but causality has not been established. Discontinue if pancreatitis is suspected." 1
  • Unlike some other antidiabetic medications, linagliptin does not require dose adjustment for renal impairment, which is an advantage for patients with kidney disease 1, 2

Monitoring and Management Recommendations

  • For patients with risk factors for pancreatitis (history of pancreatitis, gallstones, heavy alcohol use, hypertriglyceridemia), consider alternative antidiabetic agents 1
  • If pancreatitis is suspected, promptly discontinue linagliptin and initiate appropriate management 1

Comparison with Other Antidiabetic Medications

  • The risk of pancreatitis has been reported with other DPP-4 inhibitors (saxagliptin, sitagliptin) and GLP-1 receptor agonists 3, 4
  • The FDA and European Medicines Agency have not identified a definitive causal link between DPP-4 inhibitors and either pancreatitis or pancreatic cancer 3
  • For patients at high risk of pancreatitis, SGLT2 inhibitors may be an alternative option, as they have not been associated with increased pancreatitis risk 1, 5